NYSE Arca Biotech Index First Trust (FBT) 101.90

New Post Public Reply Private Reply Replies (0) Message Board

Sep 21, 2016 at 5:20 PM

NYSE Arca Biotech Index First Trust (FBT) 101.90 $FBT

Analysts Anticipate FBT Will Reach $119
ETFChannel.com - Fri Sep 16, 10:08AM CDT
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst...
FBT: 101.90 (+1.11)

Inside the Recent Surge in Biotech ETFs
Sanghamitra Saha - Zacks Investment Research - Wed Sep 14, 1:19PM CDT
What caused biotech ETFs to tack on solid gains on September 12.
PBE: 43.30 (+0.30), SBIO: 27.16 (+0.21), PRGO: 93.69 (+0.32), RPTP: 8.99 (+0.02), GILD: 81.70 (-0.08), FBT: 101.90 (+1.11), XBI: 68.28 (+0.77), FOMX: 10.26 (+0.22), HZNP: 19.17 (+0.26), IBB: 297.53 (+1.83)

Analysts See 19% Gains Ahead For FBT
ETFChannel.com - Fri Sep 09, 6:59AM CDT
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst...
FBT: 101.90 (+1.11)

Biotech ETF Industry Outlook
Zacks Equity Research - Zacks Investment Research - Wed Aug 31, 2:39PM CDT
It has been a challenging environment for the biotech industry so far; how are these ETFs expected to perform for the rest of 2016.
PBE: 43.30 (+0.30), FBT: 101.90 (+1.11), XBI: 68.28 (+0.77), BBH: 118.17 (+0.48), IBB: 297.53 (+1.83)

Did Hillary Clinton's Tweet Cause the Sell-Off in Mylan (MYL) Stock?
Ryan McQueeney - Zacks Investment Research - Wed Aug 24, 4:29PM CDT
Shares of pharmaceutical giant Mylan Inc. (MYL) fell over 5.5% in afternoon trading Wednesday after Hillary Clinton tweeted about its price hikes of the EpiPen medication.
FBT: 101.90 (+1.11), MYL: 41.91 (+0.65), IBB: 297.53 (+1.83)

Another Endorsement for Biotech ETFs
editor@etftrends.com (ETF Trends) - ETF Trends - Tue Aug 16, 10:30AM CDT
The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks the Nasdaq Biotechnology Index, and rival biotechnology exchange traded funds, seem to have put the woes experienced earlier this year behind them and recently have been in rally...
FBT: 101.90 (+1.11), XBI: 68.28 (+0.77), IBB: 297.53 (+1.83)

As Cost Panel Gets Delayed, Buy These 3 Biotech ETFs
Maher Syed - Zacks Investment Research - Thu Jun 23, 3:55PM CDT
These Biotech stocks are unique from one another, but still hold value in the way the holdings are focused. There are choices to choose from, so which one will you pick?
FBT: 101.90 (+1.11), UBIO: 31.71 (+0.64), BBH: 118.17 (+0.48)

A Catalyst for Biotech ETFs
editor@etftrends.com (ETF Trends) - ETF Trends - Mon Jun 06, 7:00AM CDT
The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), the largest biotechnology exchange traded fund, is up 9.2% over the past month. Performances for some rival biotech ETFs have been even better and that may be setting the stage for once beloved...
FBT: 101.90 (+1.11), XBI: 68.28 (+0.77), IBB: 297.53 (+1.83)

Trying to Believe in Biotech ETFs
editor@etftrends.com (ETF Trends) - ETF Trends - Fri Jun 03, 7:00AM CDT
The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), the largest biotechnology exchange traded fund, and rival biotech ETFs are vexing investors this year. Just when turnarounds for these funds look legitimate, they tumble again, prompting investors...
FBT: 101.90 (+1.11), XBI: 68.28 (+0.77), IBB: 297.53 (+1.83)

A Fed Focused on Legacy?
editor@etftrends.com (ETF Trends) - ETF Trends - Fri Jun 03, 7:00AM CDT
Note: This article appears on the ETFtrends.com Strategist Channel By Dr. Vito Sciaraffia Federal Reserve Chairperson Paul Volker is remembered for taming the rampant inflation of the late 1970s-early 1980s. Present Chairperson Janet Yellen and her...
FBT: 101.90 (+1.11), XBI: 68.28 (+0.77), IBB: 297.53 (+1.83)

Finally A Biotech ETF Bounce?
editor@etftrends.com (ETF Trends) - ETF Trends - Wed Jun 01, 7:30AM CDT
The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), the largest biotechnology exchange traded fund, and rival biotech ETFs have been tempting, even teasing investors with signs the group may be ready to rebound this year only to let market...
BIS: 29.92 (-0.41), FBT: 101.90 (+1.11), XBI: 68.28 (+0.77), IBB: 297.53 (+1.83), LABD: 16.00 (-0.64)

15 Most Read ETF Articles of the Week (May 16-20)
editor@etftrends.com (ETF Trends) - ETF Trends - Fri May 20, 4:34PM CDT
Each day ETFtrends.com publishes news, strategy and commentary on ETFs in the realms of Commodities, Currency, Equities and Smart-Beta to name a few. Here’s a look at the Top 15 Most Viewed Articles of the Week on ETF Trends, May 16-20, 2016. Click...
USO: 10.40 (+0.33), SCHZ: 53.44 (+0.06), MLN: 20.76 (+0.01), HYMB: 59.25 (unch), HYD: 32.26 (+0.01), FBT: 101.90 (+1.11), GREK: 7.14 (+0.15), XBI: 68.28 (+0.77), IBB: 297.53 (+1.83), BNO: 13.82 (+0.34), BNDX: 55.76 (+0.12), PPLT: 101.49 (+2.49), PGX: 15.19 (+0.09), SGOL: 129.81 (+1.94), FVD: 27.11 (+0.20), BSV: 80.75 (+0.02), RVNU: 27.46 (-0.07), MORT: 22.36 (+0.18), REM: 10.80 (+0.11), GLD: 127.27 (+1.83), PFF: 39.60 (+0.18), AGG: 112.03 (+0.28), IAU: 12.85 (+0.18), BND: 83.85 (+0.24)

Biotech ETFs Soar on Pfizer-Anacor Deal: SBIO, XBI in Lead
Sweta Killa - Zacks Investment Research - Tue May 17, 10:40AM CDT
Pfizer struck a deal to acquire the skin drug maker Anacor Pharmaceuticals for $5.2 billion that sent biotech ETFs higher.
AGN: 238.41 (-0.26), PBE: 43.30 (+0.30), SBIO: 27.16 (+0.21), FBT: 101.90 (+1.11), XBI: 68.28 (+0.77), PFE: 34.28 (+0.47), BBH: 118.17 (+0.48), IBB: 297.53 (+1.83), ANAC: 99.06 (-0.14)

Resisting the Temptation of Biotech ETFs
etftrends@etftrends.com (ETF Trends) - ETF Trends - Mon May 16, 7:00AM CDT
After rallying late in the first quarter and to start the current quarter, it looked liked as though biotechnology stocks and exchange traded funds were shaking the doldrums that have plagued the group dating back to last year. It appears as though...
BIS: 29.92 (-0.41), FBT: 101.90 (+1.11), XBI: 68.28 (+0.77), IBB: 297.53 (+1.83), LABD: 16.00 (-0.64), ZBIO: 19.64 (-0.32)

What Lies Ahead for Biotech ETFs?
Zacks Equity Research - Zacks Investment Research - Fri May 13, 3:48PM CDT
Should you invest in biotech ETFs now?
PBE: 43.30 (+0.30), FBT: 101.90 (+1.11), XBI: 68.28 (+0.77), BBH: 118.17 (+0.48), IBB: 297.53 (+1.83)

10 Best & Worst ETF Performers of the Day (May 11)
etftrends@etftrends.com (ETF Trends) - ETF Trends - Wed May 11, 4:04PM CDT
Welcome to the ETFtrends.com 10 Best & Worst ETF Performers of the Day for Wednesday, May 11, 2016. 10 Best ETF Performers: Sym Name Last Percent Volume UGA US Gasoline 27.57 +5.55% 93,722 SGG DJ-UBS Sugar TR Sub-Idx ETN Ipath 38.10 +5.02% 62,198...
PBE: 43.30 (+0.30), FBT: 101.90 (+1.11), XBI: 68.28 (+0.77), BNO: 13.82 (+0.34), IBB: 297.53 (+1.83), UGA: 25.94 (+0.77), EPHE: 38.23 (+0.94), XRT: 43.48 (+0.31), SBIO: 27.16 (+0.21), HEWJ: 24.81 (+0.43), GDXJ: 48.04 (+3.57), SLVP: 15.10 (+0.99), DBJP: 32.94 (+0.59), BBH: 118.17 (+0.48), FXD: 35.08 (+0.19), VIXY: 28.81 (-2.45)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

FuelCell Faces Class Action Crunch as Deadline Looms

FuelCell's Legal Storm: What to Know Now You ever get that feeling when your gut knows it all before you even finish reading the headline? Well, buckle up, because FuelCell Energy, Inc. (NASDAQ:FCEL) is staring down a potential class-action train wreck, and they ain't got much track left to skid on before the deadline hits hard on November 10th, 2026. The Crunchy Details...

Off-Broadway Play 'DUST' Raises Autism Support Funds

Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...

Evaluating GLP-1 Telehealth? Key Questions to Consider

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Invasive Procedures Don't Extend Life in Stable Heart Disease

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Historic Records Set at 2026 CNO Monumental Marathon

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Johnson & Johnson Unveils Promising PsA Treatment Data

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

ecozy's Brezzano Switch: Brewing Simplicity at Home

Breathe the aroma, sip the innovation. ecozy just threw their Brezzano Switch into the arena, and here's the deal: it's a no-nonsense, get-your-caffeine-fix kind of machine aimed at making your mornings simple without compromising on flavor. Unique Features of the Brezzano Switch So, what's cooking? Get this—it's not just any coffee contraption. Built sleek and compact,...

2027 Toy of the Year Finalists Energize Play Market

A Kaleidoscope of Innovation in Toys There's a familiar buzz in the air, folks. The 2027 Toy of the Year Awards finalists have been unveiled, and they're bringing a fresh wave of creativity to children's playrooms. These aren't just toys; they're miniature innovators ready to light up the market this holiday season. The reveal happened at the Chicago Toy & Game Fair and...